ClinicalTrials.gg
RecruitingNCT07118241Updated Oct 28, 2026

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

A Phase 2 interventional study of Recombinant Human Proteoglycan 4 and Vehicle Control in Sjögren's Syndrome, sponsored by Lubris Bio Pty Ltd. Recruiting at 7 sites in Australia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Lubris Bio Pty Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 28, 2026Site recruiting status changedStudy contact changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Sjogren's Syndrome with a site in Australia — 7 open to participants now, 11 under way, 6 of them phase 3. Sjogren's Syndrome · Australia.

Planned enrollment
12th of 18
80 · median 240
Started
2025
with 1 other
Phase 2
7 of 18
2 open now
Primary completion
2026-12
later than 3 of 10 live
Registered
13th of 18
by date
Lead sponsor
2 of 18
Lubris Bio Pty Ltd

Among the 18 studies in Sjogren's Syndrome with a site in Australia, this one is the 12th largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 3 of the 10 other live ones, and was the 13th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

7 of the 18 studies in Sjogren's Syndrome with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Sjogren's Syndrome with a site in Australia, or all of them as a file.
02

Study summary

rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.

03

Conditions studied

  • Sjögren's Syndrome

Keywords

  • Sjogrens Syndrome
  • Dry Eye
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have the ability to comprehend and provide a signed and dated consent form.
  2. Are 18-75 years at time of consent;
  3. Have been diagnosed with SS for at least 3 months prior to ICF;
  4. Have been using artificial tears as the only topical treatment of SS related dry eye for at least 30 days prior to Visit 1;
  5. Have been stably using systemic medications for at least one month prior to Visit 1;
  6. Have Global SANDE score ≥ 40;
  7. Average VAS score for typical symptoms of dry eye (dryness, foreign body sensation, burning/stinging, itching, pain, stick feeling, blurred vision and photophobia) ≥ 25 mm, none \< 5 mm;
  8. Have Oxford corneal fluorescein staining grade of ≥ 1 and ≤ 2 in each eye (OD \& OS both ≥ 1 and ≤ 2);
  9. Stated willingness to comply with all study procedures, attend all scheduled clinic visits, and continue participation for the duration of the study.
  10. Ability to self-administer study medication and willingness to adhere to the medication regimen.

Exclusion criteria

Exclusion Criteria

  1. Are currently or have a history of any ocular or systemic disorder or condition other than dry eye that based on investigator judgment will interfere with the interpretation of the study results. Examples of ocular or systemic disorders or conditions include active ocular infection, conjunctivochalasis, superior limbic keratoconjunctivitis, limbal stem cell deficiency, allergic conjunctivitis, giant papillary conjunctivitis, atopic keratoconjunctivitis, anterior basement membrane dystrophies, neurotrophic keratitis, corneal dystrophy, exposure keratitis, moderate to severe blepharitis, ocular trauma, progressive or degenerative corneal conditions, uveitis, and systemic infection;
  2. Have used any topical ocular medications (other than artificial tears), therapeutic medical devices, or undergone ocular surgery within the 30 days prior to Visit 1. Topical ocular medications include cyclosporine, lifitegrast, eye drops, and autologous/serum. Therapeutic medical devices include trigeminal stimulation, meibomian glad warming (excepting at home masks) or expression, intense pulsed light, low level light therapy, etc. Ocular surgeries include laser or refractive surgical procedures, insertion of punctal or punctal cauterization;
  3. Are unwilling to forgo the use of topical medications (other than IMP and limited artificial tear use), medical devices or ocular surgery from Visit 1 through Visit 4.
  4. Have only one eye;
  5. Are unwilling to adhere to t.i.d. administration of vehicle during run-in;
  6. Are unwilling to limit the use of artificial tears to no more than 4 days during run-in;
  7. Have begun regularly using systemic compounds for SS or SS-related dry eye during the one month prior to Visit 1. Systemic compounds include omega-3 oil (fish oil, flaxseed oil, etc.), systemic corticosteroids, , and biologics that based on investigator judgment will interfere with the interpretation of the study results.
  8. Are unwilling to maintain a stable regimen of systemic compound use during the duration of the study;
  9. Have known to one of the components of the study or procedural medications;
  10. Have participated in another clinical study at the same time as the present study or within 30 days of Visit 1;
  11. Have a history of drug, medication or alcohol abuse or addiction;
  12. Are females of (those who are not surgically sterilized or for at least 1 year) who meet any one of the following conditions:

    1. are currently pregnant or,
    2. have a positive result on the urine pregnancy test at the Screening Visit or,
    3. intend to become pregnant during the entire course of and 30 days after the study treatment periods, or,
    4. are breast-feeding or,
    5. not willing to use highly effective measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods, during the entire course of and 30 days after the study treatment periods;
  13. Are males with a female partner of child bearing potential where:

    1. the male is not surgically sterilized or,
    2. where the male partner cannot provide information regarding the female partner's child bearing status or,
    3. where the child bearing status of the female partner does not meet that of Exclusion Criteria 12; however, the female partner of a male participant will not be required meet Exclusion Criteria 12b.
  14. Have a history of a serious physical or psychiatric disorder that, in the investigator's opinion, could prevent compliance with study procedures or affect study participation;
  15. Have any other surgical or medical condition or finding that in the opinion of the investigator would compromise the subject's safety or participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Placebo comparator
    Vehicle Control

    PBS Based Vehicle Control

    Drug: Vehicle Control

  • Experimental
    rhPRG4 450ug/ml

    rhPRG4 450ug/ml

    Drug: Recombinant Human Proteoglycan 4

Interventions

  • DrugRecombinant Human Proteoglycan 4

    rhPRG4 450ug/ml

  • DrugVehicle Control

    PBS based Vehicle Conrtol

06

What researchers measure

Primary outcomes

  1. To assess the efficacy of rhPRG4 by looking at the frequency of patients attaining complete resolution of total corneal staining with fluorescein (Oxford Scale) at Day 28

    To assess the efficacy of rhPRG4 by looking at the frequency of patients attaining complete resolution of total corneal staining with fluorescein (Oxford Scale) at Day 28

    Time frame: From baseline to the end of treatment at day 28

Secondary outcomes

  1. To assess the safety of rhPRG4 by observation of the severity of treatment-emergent adverse events for the study duration

    To assess the safety of rhPRG4 by observation of the severity of treatment-emergent adverse events for the study duration

    Time frame: From baseline to day 28

  2. To assess the safety of rhPRG4 by observation of the change in BCVA over 28 days

    To assess the safety of rhPRG4 by observation of the change in BCVA over 28 days

    Time frame: From baseline to day 28

  3. To assess the safety of rhPRG4 by observation of signs evaluated by slit lamp examination (SLE) (Meibomian glands, Eyelid Erythema, Eyelid Oedema, Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Hyperemia, Corneal transparency & Corneal neo

    To assess the safety of rhPRG4 by observation of signs evaluated by slit lamp examination (SLE) (Meibomian glands, Eyelid Erythema, Eyelid Oedema, Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Hyperemia, Corneal transparency \& Corneal neovascularization)

    Time frame: From baseline to day 28

  4. To assess the safety of rhPRG4 by observation of intraocular pressure (IOP)

    To assess the safety of rhPRG4 by observation of intraocular pressure (IOP)

    Time frame: From baseline to day 28

  5. To assess the efficacy of rhPRG4 using the total VAS score for dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia (anchors: none & severe) at Day 28

    To assess the efficacy of rhPRG4 using the total VAS score for dryness, foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia (anchors: none \& severe) at Day 28

    Time frame: From baseline to day 28

  6. To assess the efficacy of rhPRG4 using the SANDE score compared to vehicle at Day 28

    To assess the efficacy of rhPRG4 using the SANDE score compared to vehicle at Day 28

    Time frame: From baseline to day 28

  7. To assess the efficacy of rhPRG4 using the Oxford staining score, both per eye and as a total score per subject compared to vehicle at Day 28

    To assess the efficacy of rhPRG4 using the Oxford staining score, both per eye and as a total score per subject compared to vehicle at Day 28

    Time frame: From baseline to day 28

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's planned 15 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jul 2026 → Dec 2026 and completion Aug 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 12, 2025
StartActual
Sep 17, 2025
Primary completionEst.
Dec 30, 2026was Jul 2026
CompletionEst.
Mar 2027was Aug 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. Sydney Eye Hospital is now Recruiting
Show site
  • The Royal Melbourne Hospital · Melbourne, Australia
across 2 updates, Oct 23, 2026 – Oct 28, 2026
Primary completion
Jul 30, 2026→Dec 30, 2026
Oct 23, 2026
Study completion
Aug 2026→Mar 2027
Oct 23, 2026
Contact
Study contact's phone or email changed: e•••@lubris.net→e•••@lubris.net. See the current contact
Oct 26, 2026
Show all 3 updates
  1. Oct 28, 2026
    Sydney Eye Hospital is now Recruiting
  2. Oct 26, 2026
    Contact Study contact's phone or email changed: e•••@lubris.net→e•••@lubris.net. See the current contact
  3. Oct 23, 2026
    1 site added
    Show site
    • The Royal Melbourne Hospital · Melbourne, Australia
    Primary completion Jul 30, 2026→Dec 30, 2026
    Study completion Aug 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07118241
Lead sponsor
Lubris Bio Pty Ltd
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Sep 17, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Edward CEO
Contact
etruitt@lubris.net
6193394016

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion